13F-HR: Axon Discloses Q2 2025 Holdings: Cellebrite Stake

Axon Enterprise, Inc. reported its Q2 2025 institutional holdings, revealing a significant stake in Cellebrite DI Ltd. ordinary shares.

Summary

• AXON ENTERPRISE, INC. filed its Form 13F-HR for the quarter ended June 30, 2025.
• The report indicates a total of 1 holding entry with a total value of $144,000,000.
• The primary holding is 9,000,000 ordinary shares of CELLEBRITE DI LTD. (CUSIP: M2197Q107).
• AXON ENTERPRISE, INC. exercises sole investment discretion over these 9,000,000 shares.
• No voting authority (sole, shared, or none) is reported for these holdings.

Sentiment

Score: 5

Explanation: The filing is a standard regulatory disclosure of institutional holdings and does not inherently convey positive or negative sentiment regarding the filer's operational performance or future prospects, beyond the factual reporting of a significant investment.

Positives

• AXON ENTERPRISE, INC. holds a substantial position in Cellebrite DI Ltd., valued at $144,000,000, indicating a significant investment conviction in the digital intelligence sector.

Negatives

• The filing indicates that AXON ENTERPRISE, INC. holds 9,000,000 ordinary shares of Cellebrite DI Ltd. with sole investment discretion, but reports zero sole, shared, or none voting authority for these shares, which is an unusual disclosure for an institutional holding.

Risks

• Investment in Cellebrite DI Ltd. is subject to market fluctuations and company-specific performance risks inherent in equity holdings.
• The absence of reported voting authority for the 9,000,000 shares of Cellebrite DI Ltd. could limit AXON's ability to influence corporate governance or strategic decisions at Cellebrite.

Future Outlook

This filing, a Form 13F-HR, reports historical equity holdings and does not provide forward-looking statements or guidance from AXON ENTERPRISE, INC. regarding its future operational outlook or investment strategy.

Industry Context

This Form 13F filing by AXON ENTERPRISE, INC. primarily reflects its investment portfolio rather than its core operational activities in public safety technology. The reported holding in Cellebrite DI Ltd., a digital intelligence company, suggests an investment in a related but distinct technology sector, potentially aligning with broader trends in data forensics and cybersecurity.

Comparison to Industry Standards

• As a Form 13F filing, this report details a specific equity holding rather than operational results, making direct comparisons to industry-standard operational benchmarks for AXON ENTERPRISE, INC. not applicable.
• The investment in Cellebrite DI Ltd. is a portfolio decision, and its performance would typically be benchmarked against digital intelligence sector peers like Magnet Forensics or OpenText, though this filing does not provide performance data or investment rationale.

Stakeholder Impact

• Shareholders of AXON ENTERPRISE, INC. gain transparency into a portion of the company's investment portfolio, specifically a significant stake in Cellebrite DI Ltd.
• For Cellebrite DI Ltd., AXON's significant holding indicates a notable institutional investor, which could be viewed positively by its own shareholders and the market.

Key Dates

Keywords

Axon, Cellebrite, 13F, Holdings, Investment, Institutional, SEC, Equity, Digital Intelligence